Clinical Trial Update: Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess [Phase 3]

View source ↗

Summary

Phase 3 placebo-controlled trial of SOM230 (pasireotide) to reduce post-pancreatectomy fistula, leak, and abscess in pancreatic cancer patients has completed an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• SOM230 (pasireotide)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Pancreatic Cancer | Phase 3 | Status: COMPLETED | Results posted: 2016-02-01